Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Accounts Payables (2022 - 2025)

Zentalis Pharmaceuticals (ZNTL) has 4 years of Accounts Payables data on record, last reported at $7.0 million in Q3 2025.

  • For Q3 2025, Accounts Payables fell 14.28% year-over-year to $7.0 million; the TTM value through Sep 2025 reached $7.0 million, down 14.28%, while the annual FY2024 figure was $7.4 million, 50.17% down from the prior year.
  • Accounts Payables reached $7.0 million in Q3 2025 per ZNTL's latest filing, up from $3.7 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $20.4 million in Q2 2024 and bottomed at $3.7 million in Q2 2025.
  • Average Accounts Payables over 4 years is $11.0 million, with a median of $11.2 million recorded in 2022.
  • Peak YoY movement for Accounts Payables: skyrocketed 66.11% in 2024, then crashed 81.81% in 2025.
  • A 4-year view of Accounts Payables shows it stood at $11.2 million in 2022, then surged by 32.71% to $14.9 million in 2023, then plummeted by 50.17% to $7.4 million in 2024, then decreased by 5.47% to $7.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accounts Payables were $7.0 million in Q3 2025, $3.7 million in Q2 2025, and $7.8 million in Q1 2025.